Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

globenewswire.com
ALNY Alnylam's drugs patisiran and vutrisiran are key to the transthyretin amyloidosis treatment market growth. The FDA approval of vutrisiran for ATTR cardiomyopathy is a significant positive development. BIIB While Biogen is a major player in the biotech sector, the article does not provide specific details about their current involvement or performance in the transthyretin amyloidosis treatment market. PFE Pfizer's Vyndaqel is a dominant targeted therapy in the transthyretin amyloidosis treatment market, contributing to its significant market share and revenue. IONS Ionis Pharmaceuticals' eplontersen is advancing through trials with improved efficacy and limited side effects, positioning it as a key pipeline therapy for the growing transthyretin amyloidosis market.

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider Austin, United States, July 07, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Transthyretin Amyloidosis Treatment Market was valued at USD 8.95 Billion in 2025 and is projected to reach USD 35.10 Billion by 2035, registering a CAGR of 14.64% during 2026–2035. Growth is supported by increasing diagnosis of ATTR cardiomyopathy (ATTR-CM), expanding use of gene-silencing therapies and TTR stabilizers, favorable regulatory approvals, and rising investment in rare disease therapeutics.

The transthyretin amyloidosis treatment market has been transformed by gene-silencing drugs like patisiran and vutrisiran that stop the liver from producing the misfolded transthyretin protein, alongside TTR stabilizers preventing misfolding through a different mechanism. In November 2024, the FDA approved Alnylam's vutrisiran as a subcutaneous RNAi therapy for ATTR cardiomyopathy, meaningfully expanding an already-approved polyneuropathy drug. Better diagnostic tools, especially nuclear cardiac imaging identifying ATTR-CM without biopsy, are driving far more patients into diagnosis and treatment than was possible a decade ago globally.

Download the Sample Transthyretin Amyloidosis Treatment Market Report (2026–2035) for detailed market size, forecasts, company profiles, competitive landscape, and regional analysis: https://www.snsinsider.com/sample-request/6932

Rising Diagnosis Rates and Pipeline Activity to Augment Market Expansion Globally

Nuclear cardiac imaging advances, especially technetium pyrophosphate scans identifying ATTR-CM without biopsy, are creating tremendous opportunity by catching far more patients than older diagnostic methods ever could. Pipeline is active in late stage with acoramidis and eplontersen working towards approval expanding available treatment options with routine genetic testing for at risk families and spreading clinician awareness positioning this market for sustained growth well beyond current approved therapies globally.

Segmentation Analysis:

By Therapy, Targeted Therapy Dominated the Market; Pipeline Therapy Segment to Register the Fastest CAGR Globally

Targeted therapy held the largest market share with 87.14% revenue in 2025, driven by thorough physician adoption of Pfizer's Vyndaqel, Alnylam's Onpattro, and Amvuttra targeting the root disease cause rather than managing symptoms with strong clinical results. Pipeline therapy is expected to register the highest CAGR during 2026–2035, driven by unusually active drug development with BridgeBio's acoramidis and Ionis Pharmaceuticals' eplontersen advancing through trials with improved efficacy and limited side effect profiles globally.

By Type, ATTR-PN Dominated the Market; ATTR-CM Segment to Register the Fastest CAGR Globally

ATTR-PN had the largest revenue share at 78.25% in 2025, due to high prevalence of hereditary transthyretin amyloidosis with neurological symptoms and earlier diagnosis and treatment of patients with patisiran, vutrisiran, and eplontersen showing real effectiveness. The ATTR-CM is expected to show the highest CAGR during 2026-2035, owing to rising awareness of cardiac diseases, improving diagnostic tools gradually, expanded cardiac indication for vutrisiran, and ageing populations most at risk for cardiac disease globally.

By Disease, Wild-Type Amyloidosis Dominated the Market; Hereditary ATTR Segment to Register the Fastest CAGR Globally

Wild-type amyloidosis was the largest revenue share contributor to the market, with 54.08% in 2025, driven by high prevalence among older adults with improved diagnostic methods and rising physician awareness bringing many more cases to light. Hereditary transthyretin amyloidosis is projected to register the highest CAGR of around 14.73% during 2026–2035 owing to the increasing adoption of genetic testing for early detection of familial cases and increased government orphan drug commercialisation aid to facilitate research funding across the world.

By Distribution Channel, Hospital Pharmacies Dominated the Market; Online Pharmacies Segment to Register the Fastest CAGR Globally

Hospital pharmacies are expected to account for the largest share of 52.31% revenue in 2025 owing to the complexity of ATTR therapy that requires intravenous administration under close monitoring with proper storage, preparation, and patient education support that integrates complicated regimens into broader care plans. The online pharmacies segment is expected to register the highest CAGR of around 14.76% during the forecast period 2026-2035 owing to the growing preference of stable-regimen patients for the convenience of home delivery at competitive prices.

Regional Insights:

North America accounted for around 46% revenue share in the transthyretin amyloidosis treatment market in 2025, owing to the established healthcare infrastructure, high disease awareness, and presence of major pharmaceutical and biotechnology companies. The high diagnosis rates, active participation in clinical trials and strong reimbursement for new therapies contribute to the regional dominance. The United States accounts for around 84% of the regional revenue.

The U.S. Transthyretin Amyloidosis Treatment Market was valued at approximately USD 3.55 Billion in 2025 and is projected to reach approximately USD 13.49 Billion by 2035, at a CAGR of 14.27%. Growth is driven by 5,000-7,000 new ATTR-CM diagnoses per year, improved diagnostic imaging and the FDA’s approval of AMVUTTRA in March 2025 as the first RNAi therapy that showed fewer cardiovascular deaths and hospitalisations for heart failure.

Europe Transthyretin Amyloidosis Treatment Market is anticipated to be USD 2.34 Billion in 2025 and projected to reach USD 8.63 Billion by 2035, growing at a CAGR of 13.92% during 2026-2035. The growth in Europe is driven by the rising awareness, early diagnosis programmes and robust healthcare infrastructure in Germany, UK and France. Germany accounts for approximately 24% of European revenues, with a strong healthcare infrastructure, early adoption of new therapies and favourable regulatory policies to support physicians in the distribution and adoption of advanced ATTR treatments.

Asia Pacific region is expected to be the fastest growing regional segment with CAGR of around 15.68%, owing to the improving healthcare infrastructure, increasing healthcare spending and growing awareness on rare genetic disorders across China, Japan and India. The large underdiagnosed patient population in the region represents large unmet need. Improving diagnostic capabilities and physician ATTR recognition are creating accelerating growth momentum through 2035.

Leading Market Players Listed in this Report are:

Buy the Complete Transthyretin Amyloidosis Treatment Market Report with market share analysis, competitive intelligence, company profiles, regional forecasts, and strategic insights: https://www.snsinsider.com/checkout/6932

Recent Developments:

Exclusive Sections of the Report (The USPs):

Transthyretin Amyloidosis Treatment Market Report Scope

Related Market Reports

Amyloidosis Treatment Market Share, 2026

Rare Disease Genetic Testing Market Analysis, 2026

mRNA Therapeutics Market Growth, 2026

mRNA Technology Market Trends, 2026

mRNA Synthesis Raw Materials Market Outlook, 2026

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.